We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 1.52% | 28.81 | 28.82 | 28.48 | 28.49 | 10,860,850 | 16:37:38 |
From May 2019 to May 2024
By Matt Grossman
Pfizer Inc. on Tuesday raised its full-year revenue and earnings guidance, citing a higher estimate of sales of its Covid-19 vaccine.
Pfizer now expects full-year revenue of $70.5 billion to $72.5 billion, compared with previous guidance for revenue of $59.4 billion to $61.4 billion.
The company forecast a full-year adjusted profit of $3.55 a share to $3.65 a share. It had previously said it expected an adjusted profit of $3.10 a share to $3.20 a share.
Pfizer expects its Covid-19 vaccine developed with BioNTech SE to generate revenue of about $26 billion in the year. It had previously guided for revenue of about $15 billion from the shot.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
May 04, 2021 07:21 ET (11:21 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
